Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05325073 · ClinicalTrials.gov registry record · Phase 4
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
A Phase 4 study of Liver Transplant Rejection, sponsored by Northwestern University.
- Active
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05325073 is a Phase 4 study of Liver Transplant Rejection that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 9 participants, below the 52-participant average among 3 other Liver Transplant Rejection trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05325073, a Phase 4 study of Liver Transplant Rejection, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.
Conditions Studied
Interventions
- DRUG Erythropoietin
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05325073
The ClinicalTrials.gov registry entry for NCT05325073 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52-participant average among 3 other Liver Transplant Rejection trials with a reported enrollment target (83% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Transplant Rejection appearing as the primary indexed condition, and to 1 intervention - of which Erythropoietin is the first listed.
NCT05325073 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05325073 about?
NCT05325073 is a clinical study titled "Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients". The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinic...
What is the current status of trial NCT05325073?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2022-02-18. Estimated completion is 2024-09-30.
What conditions does trial NCT05325073 study?
This clinical trial studies the following conditions: Liver Transplant Rejection.
What interventions are being tested in trial NCT05325073?
The interventions under investigation include: Erythropoietin (DRUG).
Who is sponsoring clinical trial NCT05325073?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05325073 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.